Skip to main content
. Author manuscript; available in PMC: 2016 Feb 9.
Published in final edited form as: Cancer Cell. 2015 Feb 9;27(2):163–175. doi: 10.1016/j.ccell.2015.01.001

Figure 1. Schematic of notable targets of BCBM formation identified in preclinical studies (see Table 1).

Figure 1

Molecules are categorized based on the stage of the metastatic cascade in which it is involved. Brain-tropic circulating tumors cells (CTC) may express a particular signature, such as EpCAM-/HER2+/EGFR+/HPSE+/Notch1+ (Zhang et al., 2013). While drug delivery into brain metastatic lesions is compromised by the BTB, the ease of access is greater than in the normal brain (with an intact BBB). Methods used to enhance drug delivery are also mentioned.